Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1sChallenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment. It’s our pre-Super Bowl show, Read More
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pillSTAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
In an unexpected move, Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal mass compounding.” In announcing its move, Hims & Hers said it would make compounded copies of Wegovy available on its platform Read More
Hims & Hers Launches Copy of Wegovy Pill, Prompting Legal ThreatsHims & Hers Launches Copy of Wegovy Pill, Prompting Legal Threats
(MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill semaglutide (Wegovy), just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation… (MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss Read More
Novo Nordisk vows legal action to protect Wegovy pillNovo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug. Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
A sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and moreA sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and more
If there’s any event that draws a lot of attention to TV ads, it’s the Super Bowl. Drug companies usually sit on the sidelines for the annual advertising bonanza, and one might expect this Sunday’s game to be no different, considering the FDA’s recent crackdown on pharma ads. But that’s not the case. Novartis and Read More
Self-Acupressure for Fatigue in Patients Surviving Ovarian CancerSelf-Acupressure for Fatigue in Patients Surviving Ovarian Cancer
This randomized clinical trial investigates whether true self-acupressure, learned through a mobile app, improves cancer-related fatigue in women surviving ovarian cancer compared with sham self-acupressure and usual care.
A reliable atlas of cell types found in breast cancersA reliable atlas of cell types found in breast cancers
Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable disease, defined as a malignancy of the epithelial ducts in breast tissue. Characterizing the vast heterogeneity within BC cells and their surrounding tumor microenvironment is crucial because this diversity is the primary reason for treatment resistance, disease progression and poor patient prognosis.
Semaglutide improves cardiovascular health but price reductions are needed to make it cost-effective, study findsSemaglutide improves cardiovascular health but price reductions are needed to make it cost-effective, study finds
Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular benefits for selected patients without diabetes who have established heart disease, but further price reductions are needed to make the therapy good value for money, according to a new analysis from researchers at Beth Israel Deaconess Medical Center (BIDMC). Semaglutide, the Read More
GLP-1 ‘Agonorexia’; Psychotic Disorders Rising in Young People; Pink Noise PitfallsGLP-1 ‘Agonorexia’; Psychotic Disorders Rising in Young People; Pink Noise Pitfalls
(MedPage Today) — Clinicians are seeing more cases of “agonorexia,” when use of GLP-1 receptor agonists turns into disordered eating. (New York Post) Colorado could become the first state to use ibogaine, a plant-based psychoactive compound… (MedPage Today) — Clinicians are seeing more cases of “agonorexia,” when use of GLP-1 receptor agonists turns into Read More
Wegovy pill in high demand in weeks since launch, Novo Nordisk saysWegovy pill in high demand in weeks since launch, Novo Nordisk says
Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January